Andre Syrota
Name: Andre
Surname: Syrota
Section: CLINICAL & VETERINARY SCIENCE
The Stakeholder Board
The Stakeholder Board (SB) is the Ultimate Decision-Making Body. The Steering Committee of the Stakeholder Board (SCSB) is the principal Working Group of the SB and can be tasked by the SB.
To form the SB, the institutions of all Member States select their representative. In addition, they provide a signed Written Statement to confirm their mandate from the institutions they represent within their Member State.
Qualification: emitting isotopes and magnetic resonance
• Neurospin facility for neuroimaging research Honours and Awards
• 2014 Commandeur of the Ordre National du Mérite, France
• 2013 Opening of the André Syrota "Clinical Research Center" on the Island of Réunion
• 2008 Officer of the Légion d'Honneur, France
• 2004 Officer of the Ordre National du Mérite, France
• 1999 Chevallier of the Légion d'Honneur, France
• Member of the French National Academy of Technology
Education and career
Email: andre.syrota 'at' inserm.fr
Membership Number: 4378
Membership type: ORDINARY
Main Country of Residence: FRANCE
Section: CLINICAL & VETERINARY SCIENCE
Username: asyrota
Elected: 2016
Homepage: https://fr.wikipedia.org/wiki/André_Syrota
Present and Previous Positions
• 2014 - present Adviser to the Administrator General of CEA
• 2014 - present Professor emeritus at the university Paris-Sud Orsay
• 2009 - 2014 President-Director general of the Institut National de la Santé et Recherche Médicale (Inserm), France
• 2014 - present Chairman of the Institute of Cancer of Toulouse
• 2014 - present Chairman of the french-german institute of translational research, Ksilink
• 1987 - present Chairman of the Scientific Advisory Board of CYROI (cyclotron of Reunion island and Indian ocean)
• 2015 - present Chairman of the board of Cermep (Center for medical research with PET)
• 2014 - present Chairman of the board of Ceph (Center for study of human polymorphism)
• 2011 - 2013 Vice-president of Science Europe, Brussels
• 2009 - 2014 President of the Alliance nationale pour les sciences de la vie et de la santé (Aviesan), France
• 1993 - 2007 Director of Life sciences at the Commissariat d'Energie Atomique (CEA), France
• 1990 - 1993 Head of research department in imaging, pharmacology & physiology, Directorate of Life sciences, CEA, France
• 1989 - 1994 Director, joint CNRS 1285-CEA “Régulation of neurotransmission in living organisms” research unit, Orsay
• 1984 - 1997, 1999-2007 Chief of nuclear medicine division, Frédéric-Joliot Hospital and CEA, Orsay
• 1979 - 2015 Professeur of biophysics and nuclear medicine, Faculty of Medicine, Kremlin-Bicêtre, university Paris Sud Orsay
• (1979-2015) Medical consultant in biophysics at the Faculty of Medicine, Kremlin-Bicêtre, university Paris Sud
Fields of Scholarship
• Nuclear medicine
• Development of positron emission tomography for medicine and medical research
• Quantitative evaluation of cardiac and CNS receptors with PET
• Non-invasive human imaging techniques with positron-emitting isotopes and magnetic resonance
• Neurospin facility for neuroimaging research
Honours and Awards
• 2014 Commandeur of the Ordre National du Mérite, France
• 2013 Opening of the André Syrota "Clinical Research Center" on the Island of Réunion
• 2008 Officer of the Légion d'Honneur, France
• 2004 Officer of the Ordre National du Mérite, France
• 1999 Chevallier of the Légion d'Honneur, France
• Member of the French National Academy of Technology
Publications
1,Cuénod C A, Denys A, Michot J L, et al. Amygdala atrophy in Alzheimer's disease: an in vivo magnetic resonance imaging study[J]. Archives of neurology, 1993, 50(9): 941-945.
2, Merlet P, Valette H, Dubois-Randé J L, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure[J]. Journal of Nuclear Medicine, 1992, 33(4): 471-477.
3, Martinot J L, Hardy P, Feline A, et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation[J]. The American journal of psychiatry, 1990.
4, Helal B O, Merlet P, Toubert M E, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy[J]. Journal of Nuclear Medicine, 2001, 42(10): 1464-1469.
5, Chiron C, Raynaud C, Mazière B, et al. Changes in regional cerebral blood flow during brain maturation in children and adolescents[J]. Journal of nuclear medicine: official publication, Society of Nuclear Medicine, 1992, 33(5): 696-703.
6, Ribeiro M J, De Lonlay P, Delzescaux T, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA[J]. Journal of Nuclear Medicine, 2005, 46(4): 560-566.
7, Attar-Lévy D, Martinot J L, Blin J, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine[J]. Biological Psychiatry, 1999, 45(2): 180-186.
8, Mazoyer B M, Tzourio N, Frak V, et al. The cortical representation of speech[J]. Journal of cognitive neuroscience, 1993, 5(4): 467-479.